Autolus Therapeutics Bolsa (NASDAQ: AUTL)

Últimas noticias sobre Autolus Therapeutics (NASDAQ:AUTL) Bolsa

Autolus Therapeutics

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics PLC

Austal Ltd

A vice-presidential debate between Tim Walz and J.D. Vance has voters split on who won the 90-minute contest and could have minimal impact on the <a href="https://www.benzinga.com/topic/2024-election">2024 presidential election</a>.
Politico Poll Results: According to a Politico poll, the<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41107455/walz-vs-vance-vp-debate-betting-odds-what-candidate-is-favored-plus-how-to-watch-likely-to" target="_blank" rel="noopener"> highly anticipated debate</a> hosted by Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) unit CBS News may have a split winner.
The <a href="https://www.politico.com/news/2024/10/02/politico-snap-poll-division-debate-00182131">poll </a>of 902 people asking who won the VP debate produced a 50%/50% result for Vance and Walz.
"The dead-heat results are a fitting reflection of the country's hyper-polarized politics – particularly as it enters the final stretch of the closest presidential election in years," Politico writes.
While there was no overall winner, each candidate and their respective political parties could have something to brag about.
Walz won among independent voters with 58% of the vote, ahead of Vance's 42%. Walz also polled strong as the debate winner among younger voters, Black voters and Latino voters.
Vance won the debate according to people over the age of 55, White voters and voters with a college degree.
Politico said both men and women were split on a winner, voting 50%/50% for Vance and Walz. This could be an important win for Vance, as female voters have sided with Kamala Harris in recent 2024 election polls.
Politico asked which candidate would be a better vice president, regardless of if a voter watched the debate. This question also saw an equal split, with Vance and Walz each getting 47%, while 7% of voters were unsure.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100224">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
 Washington Post Poll Results: A <a href="https://www.washingtonpost.com/elections/interactive/2024/vice-presidential-debate-voter-poll/?utm_source=briefing&amp;utm_medium=email&amp;utm_campaign=washington_am&amp;utm_content=100224">survey </a>from the Washington Post engaged swing state voters who remain undecided between voting for Harris or Donald Trump in the 2024 election.
Ahead of the VP debate, the survey of 23 voters broke down as follows:
<ul>
<li>Probably Voting Harris: 9</li>
<li>Probably Voting Trump: 12</li>
<li>Undecided: 2</li>
</ul>
The survey found that 12 voters, representing the majority, believed Vance won the debate, while eight voters thought Walz performed better.
After the debate, the voters were asked again how they would vote in the 2024 election, which broke down as follows:
<ul>
<li>Definitely Voting Harris: 6</li>
<li>Probably Voting Harris: 3</li>
<li>Undecided: 1</li>
<li>Probably Voting Trump: 8</li>
<li>Definitely Voting Trump: 5</li>
</ul>
The Washington Post survey of swing state voters showed that Vance's performance in the VP debate may have won over support for the Republican Party. 
One of the voters who said they were leaning towards voting for Harris moved to probably voting for Trump after the debate. Of the two undecided voters before the debate, one leaned toward voting for Harris, contributing to a mixed outcome for the candidates.
Why It's Important: As <a href="https://www.benzinga.com/news/24/10/41136119/vance-vs-walz-flash-poll-picks-this-candidate-as-tuesdays-debate-winner-but-he-falls-short-in-favora">Benzinga shared earlier,</a> a CNN flash poll found a mixed result, with 51% saying Vance won the debate and 49% saying Walz won.
The post VP debate poll also found that Walz had a +37 point net favorability, while Vance had a -3 point net favorability. The net favorability rankings ahead of the VP debate were +14 points and -22 points for Walz and Vance respectively.
Both candidates gained support from the vice-presidential debate.
One remaining question is how many people watched the VP debate with the ratings still to come. A <a href="https://x.com/Benzinga/status/1841287462003327053">poll done by Benzinga </a>on X showed that only 46.2% were planning on watching the debate, with 24.2% saying they would watch the debate.
While the polls point to a mixed result, Vance likely has a slight edge in several polls and metrics. This could be good news for crypto bettors who backed the Democratic candidate as the winner on the prediction market Polymarket.
Walz was heavily favored to win the VP debate, with Polymarket giving him a 73% chance ahead of the event. However, by Wednesday morning, following Tuesday's debate, his odds had dropped to 39%, according to a YouGov poll.
A recent <a href="https://www.benzinga.com/general/politics/24/10/41132643/harris-vs-trump-vice-president-leads-former-president-by-5-points-walz-favorability-rating-tops-">weekly Morning Consult poll </a>showed Harris with a five-point lead. The same poll showed Walz with a net favorability rating of +6 and Vance with a net favorability of -9.
Next week's poll could reveal whether the VP debate further influenced favorability rankings for Vance and Walz, as well as its impact on the head-to-head matchup between Harris and Trump.
Vote for your winner in the debate in Benzinga&#8217;s poll below: 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Who won the debate?
&mdash; Benzinga (@Benzinga) <a href="https://twitter.com/Benzinga/status/1841456897662308797?ref_src=twsrc%5Etfw">October 2, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100224">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a> <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100224"> </a></li>
</ul>
Photo: Shutterstock

Politics

PARA

PARAA

Walz vs. Vance: Who Won VP Debate, And Could The Outcome Shift 2024 Election For Harris Or Trump?

Epic Games CEO Tim Sweeney declared the company "financially sound" during a presentation at <a href="https://www.benzinga.com/general/gaming">Unreal Fest 2024. </a>
This statement comes after a tumultuous period marked by significant layoffs and strategic divestitures.
<h3 class="wp-block-heading">The Layoffs And Strategic Shifts</h3>
In September 2023, Tencent ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) backed Epic Games made headlines when it announced a massive reduction in its workforce, laying off approximately 830 employees—about 16% of its total staff.
See Also: <a href="https://www.benzinga.com/general/gaming/24/10/41126126/fortnite-just-made-parenting-easier-how-to-control-your-kids-playtime-with-latest-update">Fortnite Just Made Parenting Easier: How To Control Your Kid&#8217;s Playtime With Latest Update</a>
Alongside the layoffs, Epic divested its music service platform Bandcamp and spun off the majority of SuperAwesome, a child-safe technology company. These moves resulted in the exit of around 250 additional staff members.
At the time of the layoffs, Sweeney said that Epic had been "spending way more money than we earn," pointing out the need for a "major structural change to our economics." 
Furthermore, he noted that the explosive growth of Fortnite — which initially funded the company's expansion — had transitioned to a model with lower profit margins due to revenue-sharing with creators.
<h3 class="wp-block-heading">A Year Of Rebuilding And Record Success</h3>
Fast-forward to Unreal Fest 2024, and Sweeney presented a much more optimistic view of Epic's state.
&#8220;I&#8217;m happy to tell you now that the company is financially sound, and that Fortnite and the Epic Games Store have hit new records in concurrency and success,&#8221; he said, <a href="https://www.gamesindustry.biz/epic-games-ceo-says-company-is-now-financially-sound">according</a> to GamesIndustry.biz-
And added: "We spent the last year rebuilding and really executing solidly on all fronts." 
Fortnite reached 110 million monthly active users (MAUs) during the recent holiday season. This milestone shows the game&#8217;s lasting appeal even seven years post-launch, marking a significant increase from the 78.3 million MAUs reported in August 2018. 
While Epic Games remains in a competitive struggle with Steam for dominance in the PC gaming market, the Epic Games Store reported 70 million MAUs in the last month. However, the store continues to operate at a loss, facing challenges in converting its growing user base into profitability.
<h3 class="wp-block-heading">Legal Challenges And Financial Implications</h3>
Meanwhile, Epic Games is still navigating a complex legal landscape. Sweeney has openly stated that the company&#8217;s ongoing litigation against <a href="https://www.benzinga.com/general/gaming/24/08/40423388/epic-games-mobile-store-goes-live-in-europe-ceo-says-apple-had-to-be-challenged">tech giants like Apple </a>and Google has cost Epic around $1 billion. 
The legal battles primarily stem from Epic&#8217;s attempt to create a competing app store for mobile devices, which has led to a series of costly disputes.
In a fresh move, Epic has initiated another lawsuit against Samsung and Google regarding a feature known as Auto Blocker, which complicates the installation of Epic Games on mobile devices. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/09/41098067/epic-games-files-new-antitrust-lawsuit-against-google-samsung-over-app-store-restrictions">Epic Games Files New Antitrust Lawsuit Against Google, Samsung Over App Store Restrictions</a></li>
</ul>
Image credits: Shutterstock.

Gaming

News

General

TCEHY

Epic Games Is Now 'Financially Sound,' Says CEO Tim Sweeney After Major Layoffs

Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) has outperformed the market over the past 5 years by 19.27% on an annualized basis producing an average annual return of 33.81%. Currently, Riot Platforms has a market capitalization of $2.19 billion. 
Buying $100 In RIOT: If an investor had bought $100 of RIOT stock 5 years ago, it would be worth $421.51 today based on a price of $7.23 for RIOT at the time of writing.
<h3>Riot Platforms's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727901324_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

RIOT

Here's How Much $100 Invested In Riot Platforms 5 Years Ago Would Be Worth Today

Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) has outperformed the market over the past 20 years by 2.39% on an annualized basis producing an average annual return of 10.81%. Currently, Ecolab has a market capitalization of $72.26 billion. 
Buying $100 In ECL: If an investor had bought $100 of ECL stock 20 years ago, it would be worth $781.21 today based on a price of $253.97 for ECL at the time of writing.
<h3>Ecolab's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727901319_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Ecolab 20 Years Ago Would Be Worth Today

President Joe Biden and his administration purchased an additional <a href="https://www.benzinga.com/markets/eurozone/24/10/41146905/geopolitical-risks-may-be-biggest-threat-to-markets-boe-says">6 million barrels of crude oil</a> earlier this week. 
The acquisition is meant to fill the Strategic Petroleum Reserve. The price tag came in at an average price of $68.56 per barrel, according to Patrick De Haan aka <a href="https://x.com/GasBuddyGuy/status/1840864888291242330">@GasBuddyGuy on X.</a> 
This is just the latest move in a series of oil trades executed by Biden's administration to stabilize the market.
Read Also: <a href="https://www.benzinga.com/trading-ideas/24/10/41144492/brent-crude-oil-prices-rise-amid-geopolitical-tensions">Brent Crude Oil Prices Rise Amid Geopolitical Tensions</a>
The Context: In 2022, Biden ordered the release of more than 100 million barrels of <a href="https://www.benzinga.com/government/24/02/36914512/biden-the-master-oil-trader-part-iii-president-refills-emergency-stash-as-crude-price-slides">oil from the SPR </a>after Russia invaded Ukraine. That created a supply shock in the oil markets. At the time, oil sold for more than $100 per barrel. But, through the release of oil from the SPR, Biden's administration managed to calm the markets, with oil returning to a more normal price of around $80 per barrel. Since then, Biden's team has used periods of weakness in the oil markets to repurchase oil to refill the reserve after releasing a significant amount in 2022.<a href="https://www.benzinga.com/trading-ideas/24/10/41144492/brent-crude-oil-prices-rise-amid-geopolitical-tensions"> </a><a href="https://www.benzinga.com/trading-ideas/24/10/41144492/brent-crude-oil-prices-rise-amid-geopolitical-tensions"> </a>"DOE announces another 6 million barrels of crude oil have been purchased for the SPR, for delivery Feb thru May of 2025," <a href="https://x.com/GasBuddyGuy/status/1840864888291242330">De Haan tweeted Monday.</a> "DOE has now purchased over 55 million barrels to refill the SPR."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">BREAKING: DOE announces another 6 million barrels of crude oil have been purchased for the SPR, for delivery Feb thru May of 2025. DOE has now purchased over 55 million barrels to refill the SPR.
&mdash; Patrick De Haan &#x26fd;&#xFE0F;&#x1f4ca; (@GasBuddyGuy) <a href="https://twitter.com/GasBuddyGuy/status/1840864888291242330?ref_src=twsrc%5Etfw">September 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Quoted: Todd Campbell, the editor-in-chief of TheStreet,<a href="https://x.com/ebcapital/status/1840923025690018087"> responded </a>to De Haan's tweet, saying Biden's move "has to be one of the best oil trades in history." While the administration still has not fully refilled the SPR to its pre-Russia invasion levels, the trades showcase how governments may intervene to help stabilize markets in times of uncertainty. When Biden originally released millions of barrels of oil from the SPR, gas prices were skyrocketing, putting pressure on American consumers. The release from the SPR led to a 40-cent-per-gallon decrease in gas prices, according to the Department of Energy. Now, as gas prices have returned to relatively normal levels, the administration's focus has shifted to refilling the SPR. On Wednesday, the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), a fund that roughly tracks the price of oil, fell by more than 2% intraday amid ongoing unrest and uncertainty in the Middle East. The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) also fell early in the trading day, but erased some of those losses and was in the green as of late in Wednesday's session. Keep Reading: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41143156/oil-prices-spike-energy-stocks-jump-after-irans-missile-attack-on-israel-what-investors-need-to-know">Oil Prices Spike, Energy Stocks Jump After Iran&#8217;s Missile Attack On Israel: What Investors Need To Know</a></li>
</ul>
Image: Shutterstock

Commodities

Markets

Biden The Master Oil Trader Part IV? President Loads Up On Millions Of Barrels To Refill Emergency Stash In 'One Of The Best Oil Trades In History'

<ul>
<li>Maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the Company's common shares, with 1,507,328 shares repurchased for USD 11,629,758 as of the date hereof. &nbsp;</li>
<li>A period from and including 5 October 2024 to and including 4 October 2025.
<ul>
<li>The share buy-backs will be carried out by way of repurchases in the market, both on the Oslo Stock Exchange and on Nasdaq.</li>
</ul>
</li>
</ul>

Buybacks

GOGL

Golden Ocean Group Extends Existing Buy-Back Program With 12 Months

Maryland American Water Receives Commission Approval For Acquisition Of Severn Water Company For ~$1.6M

Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) shares are trading lower following the company&#8217;s third-quarter financial results released after Wednesday&#8217;s closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/10/b41150661/levi-strauss-co-reports-third-quarter-2024-financial-results">details from the report. </a>
The Details: Levi Strauss reported quarterly earnings of 33 cents per share, which beat the analyst consensus estimate of 31 cents. Quarterly revenue came in at $1.516 billion, which missed the analyst consensus estimate of $1.55 billion.
<ul>
<li>DTC (Direct-to-Consumer) net revenues increased 10% on a reported basis and 12% on a constant-currency basis. DTC growth reflected a 12% increase in the U.S. and a 9% increase in Europe.</li>
<li>Wholesale net revenues decreased 6% on a reported basis and 5% on a constant-currency basis. Adjusting for the exit of the Denizen business, wholesale net revenues declined 3%.</li>
<li>Operating margin was 2.0% compared to 2.3% in the same quarter last year inclusive of an impairment charge of $111 million related to the Beyond Yoga acquisition.</li>
<li>Gross margin increased 440 basis points to 60% from 55.6% in the same quarter last year primarily driven by lower product costs and favorable channel and brand mix.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/24/10/41129365/what-happened-with-rivian-stock-today">What Happened With Rivian Stock Today?</a>
&#8220;The underlying fundamentals of our business are getting stronger, driven by the Levi&#8217;s&#xAE; brand, which grew 5% globally in Q3, a significant acceleration from H1 and the highest revenue growth in two years. We are making progress against our strategic priorities, including double-digit growth in our direct-to-consumer business, continued positive performance in the U.S., and Europe inflecting to growth,&#8221; said Michelle Gass, CEO of Levi Strauss &amp; Co.
Outlook: Levi Strauss sees fiscal year 2024 adjusted earnings at a mid-point of between $1.17 and $1.27 per share, versus the $1.25 estimate. 
LEVI Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Levi Strauss shares are down 6.22% after-hours at $19.75 after dropping 2.86% in Wednesday&#8217;s regular trading session.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41104861/elon-musk-tesla-win-dismissal-of-full-self-driving-claims-judge-tosses-lawsuit">Elon Musk, Tesla Win Dismissal Of Full-Self Driving Claims: Judge Tosses Lawsuit</a></li>
</ul>
Photo: Courtesy of Levi Strauss &amp; Co.

Earnings

After-Hours Center

Movers

LEVI

Levi Strauss & Co Stock Falls After Mixed Q3 Results: EPS Beat, Revenues Miss

The Lydian Includes 129 Homes And 23K Sq Ft Of Office/Retail Space; Acquisition Financed Through $35M Mortgage Debt, $14.5M In Operating Partnership Units, And Cash

Centerspace Expands Denver Presence With $54M Acquisition Of The Lydian; Completes Redemption Of 6.625% Series C Preferred Shares; YTD ATM Sales Of 1.59M Shares With $113.73M In Gross Proceeds Used For Preferred Share Redemption And Debt Pay Down

Whales with a lot of money to spend have taken a noticeably bearish stance on Zscaler.
Looking at options history for Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 55% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $365,000 and 7, calls, for a total amount of $1,123,045.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $135.0 to $230.0 for Zscaler over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Zscaler's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Zscaler's substantial trades, within a strike price spectrum from $135.0 to $230.0 over the preceding 30 days.
<h3>Zscaler 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727901137_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$11.6</td>
<td>$10.85</td>
<td>$11.25</td>
<td>$180.00</td>
<td>$675.0K</td>
<td>820</td>
<td style="text-align: right;">600</td>
</tr>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$11.3</td>
<td>$10.65</td>
<td>$11.0</td>
<td>$135.00</td>
<td>$275.0K</td>
<td>18</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$40.7</td>
<td>$40.55</td>
<td>$40.55</td>
<td>$145.00</td>
<td>$93.2K</td>
<td>108</td>
<td style="text-align: right;">23</td>
</tr>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$8.1</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$175.00</td>
<td>$90.0K</td>
<td>253</td>
<td style="text-align: right;">120</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$38.0</td>
<td>$37.3</td>
<td>$37.3</td>
<td>$150.00</td>
<td>$89.5K</td>
<td>2.6K</td>
<td style="text-align: right;">95</td>
</tr>
</tbody>
</table>

<h3>About Zscaler</h3>
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
Following our analysis of the options activities associated with Zscaler, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Zscaler</h3>
<ul>
<li>With a volume of 1,255,322, the price of ZS is up 1.52% at $169.53. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 54 days.</li>
</ul>
<h3>What Analysts Are Saying About Zscaler</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $206.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Zscaler with a target price of $220. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Zscaler, which currently sits at a price target of $200. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Strong Buy rating for Zscaler, targeting a price of $235. 
&#x2A; Consistent in their evaluation, an analyst from BTIG keeps a Buy rating on Zscaler with a target price of $205. 
&#x2A; An analyst from Cantor Fitzgerald has decided to maintain their Neutral rating on Zscaler, which currently sits at a price target of $170. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Zscaler, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Decoding Zscaler's Options Activity: What's the Big Picture?

Whales with a lot of money to spend have taken a noticeably bearish stance on Accenture.
Looking at options history for Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $260,055 and 3, calls, for a total amount of $120,743.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $320.0 and $380.0 for Accenture, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Accenture's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Accenture's significant trades, within a strike price range of $320.0 to $380.0, over the past month.
<h3>Accenture Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727901133_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$35.7</td>
<td>$33.8</td>
<td>$35.7</td>
<td>$370.00</td>
<td>$89.2K</td>
<td>62</td>
<td style="text-align: right;">35</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.7</td>
<td>$15.6</td>
<td>$15.6</td>
<td>$360.00</td>
<td>$56.1K</td>
<td>1.0K</td>
<td style="text-align: right;">49</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$1.5</td>
<td>$1.45</td>
<td>$1.5</td>
<td>$325.00</td>
<td>$47.2K</td>
<td>252</td>
<td style="text-align: right;">331</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$27.7</td>
<td>$26.8</td>
<td>$27.7</td>
<td>$370.00</td>
<td>$38.7K</td>
<td>57</td>
<td style="text-align: right;">18</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$35.6</td>
<td>$33.2</td>
<td>$35.6</td>
<td>$370.00</td>
<td>$35.6K</td>
<td>62</td>
<td style="text-align: right;">50</td>
</tr>
</tbody>
</table>

<h3>About Accenture</h3>
Accenture is a leading global IT-services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture employs just under 500,000 people throughout 200 cities in 51 countries.
After a thorough review of the options trading surrounding Accenture, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Accenture</h3>
<ul>
<li>With a volume of 2,228,852, the price of ACN is up 1.22% at $356.29. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>Expert Opinions on Accenture</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $376.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Accenture, which currently sits at a price target of $388. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Accenture with a target price of $376. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Accenture, targeting a price of $329. 
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Market Perform rating on Accenture with a target price of $390. 
&#x2A; Showing optimism, an analyst from TD Cowen upgrades its rating to Buy with a revised price target of $400. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Accenture with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Spotlight on Accenture: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 44 trades.
If we consider the specifics of each trade, it is accurate to state that 63% of the investors opened trades with bullish expectations and 29% with bearish.
From the overall spotted trades, 30 are puts, for a total amount of $2,727,271 and 14, calls, for a total amount of $652,606.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $175.0 for Moderna over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1078.22 with a total volume of 29,102.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $40.0 to $175.0 over the last 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727901128_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$8.25</td>
<td>$8.0</td>
<td>$8.05</td>
<td>$55.00</td>
<td>$1.0M</td>
<td>1.4K</td>
<td>1.2K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.9</td>
<td>$22.0</td>
<td>$22.4</td>
<td>$75.00</td>
<td>$232.9K</td>
<td>1.3K</td>
<td>104</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.15</td>
<td>$5.75</td>
<td>$6.05</td>
<td>$50.00</td>
<td>$229.2K</td>
<td>1.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$8.9</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$95.00</td>
<td>$138.6K</td>
<td>5</td>
<td>198</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$37.4</td>
<td>$37.3</td>
<td>$37.4</td>
<td>$100.00</td>
<td>$127.1K</td>
<td>3.5K</td>
<td>34</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Trading volume stands at 4,087,379, with MRNA's price down by -1.17%, positioned at $63.18.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

MRNA

Moderna Unusual Options Activity For October 02

Management

HTBK

Heritage Commerce Appoints Thomas Sa As COO Of Company And The Bank

<h3>Gainers</h3>
<ul>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) stock increased by 15.6% to $0.55 during Wednesday's after-market session. The company's market cap stands at $38.6 million. </li>
<li>Jowell Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JWEL#NASDAQ">JWEL</a>) shares increased by 11.16% to $2.27. The company's market cap stands at $4.9 million. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) stock increased by 9.55% to $0.37. The market value of their outstanding shares is at $22.3 million. </li>
<li>AYRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) shares moved upwards by 4.99% to $0.86. The company's market cap stands at $5.9 million. </li>
<li>Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) shares increased by 4.98% to $27.57. The market value of their outstanding shares is at $428.9 million. </li>
<li>Yoshitsu Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) shares moved upwards by 4.91% to $0.58. The market value of their outstanding shares is at $24.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) shares fell 7.0% to $19.58 during Wednesday's after-market session. The company's market cap stands at $7.7 billion. As per the news, the Q3 earnings report came out today. </li>
<li>E-Home Household Service (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock decreased by 3.81% to $1.01. The market value of their outstanding shares is at $8.6 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares fell 3.81% to $1.01. The market value of their outstanding shares is at $57.0 million. </li>
<li>Genius Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares fell 3.73% to $0.9. The market value of their outstanding shares is at $19.5 million. </li>
<li>Life Time Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) shares decreased by 3.42% to $23.2. The market value of their outstanding shares is at $4.7 billion. </li>
<li>SRIVARU Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares fell 2.44% to $0.08. The company's market cap stands at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIEV

AYRO

JWEL

KXIN

LOVE

SVMH

TKLF

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock rose 31.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $9.6 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares rose 30.07% to $1.73. The market value of their outstanding shares is at $5.6 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock rose 8.83% to $0.28. </li>
<li>Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) shares increased by 7.94% to $2.31. The market value of their outstanding shares is at $29.9 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock moved upwards by 7.89% to $1.64. The company's market cap stands at $2.9 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares increased by 7.36% to $0.1. The market value of their outstanding shares is at $9.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock declined by 8.6% to $4.45 during Wednesday's after-market session. The company's market cap stands at $10.1 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 6.34% to $0.28. The company's market cap stands at $2.1 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock decreased by 5.3% to $1.25. The company's market cap stands at $16.0 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock declined by 4.77% to $1.0. The market value of their outstanding shares is at $226.2 million. </li>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) shares fell 4.75% to $2.21. The market value of their outstanding shares is at $105.9 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares fell 4.66% to $1.64. The market value of their outstanding shares is at $3.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

CPHI

CTCX

EGRX

GOSS

GUTS

KAPA

PCSA

SNGX

TNFA

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Graphex Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#AMEX">GRFX</a>) stock moved upwards by 15.0% to $0.24 during Wednesday's after-market session. The market value of their outstanding shares is at $12.1 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) stock rose 3.96% to $1.05. The company's market cap stands at $83.5 million. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) stock increased by 3.94% to $0.14. The market value of their outstanding shares is at $20.4 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) shares increased by 3.63% to $0.23. The company's market cap stands at $8.7 million. </li>
<li>AgEagle Aerial Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) shares rose 3.39% to $0.14. The market value of their outstanding shares is at $2.0 million. </li>
<li>Castor Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRM#NASDAQ">CTRM</a>) shares moved upwards by 2.93% to $4.43. The market value of their outstanding shares is at $42.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nixxy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) shares declined by 9.5% to $2.1 during Wednesday's after-market session. The market value of their outstanding shares is at $8.4 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) stock decreased by 8.81% to $0.67. The market value of their outstanding shares is at $8.5 million. </li>
<li>XCHG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) shares declined by 8.68% to $13.26. The company's market cap stands at $786.6 million. </li>
<li>Polar Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) stock decreased by 5.0% to $0.49. The market value of their outstanding shares is at $8.6 million. </li>
<li>Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) stock decreased by 4.77% to $1.6. The market value of their outstanding shares is at $20.5 million. </li>
<li>Singularity Future Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLY#NASDAQ">SGLY</a>) stock declined by 4.57% to $1.67. The company's market cap stands at $5.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTRM

GPUS

GRFX

IPDN

LGCL

NIXX

POLA

SGLY

SRFM

UAVS

VCIG

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>AMTD Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) shares increased by 33.6% to $5.22 during Wednesday's after-market session. The market value of their outstanding shares is at $1.0 billion. </li>
<li>CCSC Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) stock moved upwards by 11.06% to $1.6. The company's market cap stands at $18.5 million. </li>
<li>Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) stock rose 7.69% to $4.2. The market value of their outstanding shares is at $661.7 million. </li>
<li>Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) stock rose 6.15% to $0.77. The company's market cap stands at $13.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Iveda Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) shares moved upwards by 4.34% to $1.68. The market value of their outstanding shares is at $3.7 million. </li>
<li>Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) stock moved upwards by 4.0% to $2.6. The market value of their outstanding shares is at $156.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) shares decreased by 4.2% to $2.06 during Wednesday's after-market session. The market value of their outstanding shares is at $4.0 million. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares fell 3.75% to $0.38. The market value of their outstanding shares is at $5.6 million. </li>
<li>MMTEC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares fell 3.54% to $0.74. The company's market cap stands at $147.3 million. </li>
<li>Intchains Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) shares decreased by 3.02% to $4.5. The company's market cap stands at $270.0 million. </li>
<li>Netgear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTGR#NASDAQ">NTGR</a>) shares decreased by 2.79% to $19.25. The market value of their outstanding shares is at $559.5 million. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) stock declined by 2.59% to $1.13. The company's market cap stands at $18.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTCS

CCTG

EVLV

IFBD

IVDA

NTGR

VRAR

12 Information Technology Stocks Moving In Wednesday's After-Market Session

WIIM

SPRO

Spero Therapeutics shares are trading higher after the company announced the publication of data from its Phase 1 clinical trial, which assessed the intrapulmonary pharmacokinetics of SPR719.

Plans To Increase Valuation And Regain Compliance; Shares Will Continue Trading With ".BC" Designation Indicating Below Compliance Status; No Immediate Impact On Business Operations Or SEC Reporting Requirements

Know Labs Receives NYSE American Noncompliance Notice For Not Meeting Listing Standards

Biotech

Spero Therapeutics Publishes SPR720 Phase 1 Lung Exposure Data In Antimicrobial Agents And Chemotherapy

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Autolus Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/autl-stock-quote/">AUTL</a>) just reported results for the second quarter of 2024.<ul><li>Autolus Therapeutics reported earnings per share of -22 cents. This was below the analyst estimate for EPS of -19 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/autl-stock-earnings-autolus-therapeutics-for-q2-of-2024/">AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024

Analyst Gil Blum of Needham maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), retaining the price target of $9.00. Gil Blum...

Positive Outlook for Autolus Therapeutics with Upcoming Obe-cel Approvals and Promising Clinical Trials

Deutsche Bank analyst James Shin reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price target of $10.00. J...

Buy Rating Affirmed for Autolus Therapeutics Amid Strong Commercial Prospects and Solid Financials

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Autolus Therapeutics plc 2024 Q2 - Results - Earnings Call Presentation

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Autolus Therapeutics (AUTL – Research Report), DaVita (DVA – Rese...

Analysts Conflicted on These Healthcare Names: Autolus Therapeutics (AUTL), DaVita (DVA) and Bruker (BRKR)

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Autolus Therapeutics reports 1H results

Autolus Therapeutics ( ($AUTL) ) just unveiled an announcement. Autolus Therapeutics plc is set to present key updates at the KBC Life Sciences Con...

Autolus Therapeutics Highlights Advances at Life Sciences Conference

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report). Th...

Autolus Therapeutics (AUTL) Gets a Buy from Truist Financial

AUTL

BRKR

Press Releases

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

Health Care

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

Comments

Autolus Therapeutics

Noticias

Últimas noticias sobre Autolus Therapeutics (NASDAQ:AUTL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL